Phase II study of continuous venous infusion of 5-fluorouracil in advanced pancreatic cancer.
Continuous venous infusion of 5-fluorouracil (5FU) was investigated in 18 patients with measureable advanced cancer of the pancreas. 5FU was given for 7 days in a dose of 500 mg/m2 by continuous venous infusion over a 24-hour period and then followed by a dose of 170 mg/m2 for more than 28 days. Ten patients had no change including 1 patient with minor response, and 4 patients had disease progression. Serum CA19-9 levels were measured serially after chemotherapy in 13 of 14 evaluable patients. In 3 of 10 patients who showed high levels before treatment, serum CA19-9 levels were significantly decreasing after treatment.
Tajiri
H
H
Department of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan.
Yoshimori
M
M
Okazaki
N
N
Miyaji
M
M
D000368:Aged; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis; D004341:Drug Evaluation; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000276:immunology
D015295:Antigens, Tumor-Associated, Carbohydrate; D005472:Fluorouracil